Quick Answer
Theriva Biologics, Inc. reported Net Income Loss of -$18.35 million for the year ending 2023.
- Theriva Biologics, Inc. showed an increase of +6.8% in Net Income Loss from 2022 to 2023.
- This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2024.
- XBRL data for this metric is available from 2010 to 2023 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2010 to 2023), Theriva Biologics, Inc.'s Net Income Loss has declined by 972.4%.
- Historical annual values: Fiscal year 2023: -$18.35 million | Fiscal year 2022: -$19.69 million | Fiscal year 2021: -$14.27 million | Fiscal year 2020: -$10.04 million | Fiscal year 2019: -$15.30 million | Fiscal year 2018: -$13.37 million | Fiscal year 2017: -$15.17 million | Fiscal year 2016: -$27.26 million | Fiscal year 2015: -$43.74 million | Fiscal year 2014: -$19.78 million | Fiscal year 2013: -$12.32 million | Fiscal year 2012: -$17.07 million | Fiscal year 2011: -$8.15 million | Fiscal year 2010: -$1.71 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: